Hospital
Umass Memorial Healthalliance Clinton Hospital INC
Umass Memorial Healthalliance Clinton Hospital INC was paid $82.60M by Medicaid between Jan 2018 and Dec 2024, across 406 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 11% of everything it billed.
33Billing provider infoUMASS MEMORIAL HEALTHALLIANCE CLINTON HOSPITAL INC
LEOMINSTER, MA 01453
LEOMINSTER, MA 01453
33aNPI1013995133assigned 01/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$82.60M
24GClaims1,990,855
24DCodes billed406
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#18 of 66
Median peer was paid$29.11M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 282,947 | $13.25M | |
| 2019 | 295,333 | $11.37M | |
| 2020 | 246,768 | $9.13M | |
| 2021 | 301,144 | $10.92M | |
| 2022 | 294,196 | $12.11M | |
| 2023 | 307,295 | $13.19M | |
| 2024incomplete | 263,172 | $12.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 52,887 | 45,418 | $9.17M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 24,064 | 20,831 | $8.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 46,761 | 42,226 | $7.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 46,919 | 43,465 | $7.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.7% | 41,166 | 38,022 | $6.32M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 20,531 | 18,277 | $3.33M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 51,530 | 16,708 | $3.28M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.1% | 16,438 | 15,577 | $2.53M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.5% | 18,823 | 17,775 | $2.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 12,603 | 12,134 | $1.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 12,866 | 12,204 | $1.94M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 23,570 | 21,758 | $1.64M |
394 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 9,863 | $1.26M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 9,794 | $1.18M |
| S9485 | Crisis intervention mental health services, per diem | 1.4% | 2,603 | $1.18M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 4,572 | $1.13M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 6,187 | $1.01M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 8,052 | $893K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 32,750 | $794K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 11,626 | $558K |
| 97161 | <1% | 8,281 | $542K | |
| 20611 | <1% | 1,347 | $483K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,658 | $477K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,891 | $476K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,695 | $462K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,934 | $450K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,314 | $449K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 97,287 | $416K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,208 | $410K |
| G0378 | Hospital observation service, per hour | <1% | 6,745 | $392K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,012 | $381K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,158 | $373K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,333 | $354K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,992 | $336K |
| 59025 | Fetal non-stress test | <1% | 1,332 | $330K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,145 | $327K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,472 | $318K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,485 | $314K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16,290 | $286K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,299 | $264K |
| 76830 | Ultrasound, transvaginal | <1% | 2,581 | $255K |
| 12001 | <1% | 1,141 | $249K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,002 | $245K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,556 | $239K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,421 | $238K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,673 | $217K |
| 93971 | <1% | 1,138 | $208K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,465 | $207K |
| 76642 | <1% | 2,492 | $201K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 179 | $197K |
| 93975 | <1% | 1,939 | $196K | |
| 84484 | <1% | 32,270 | $190K | |
| 76770 | <1% | 1,499 | $186K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,082 | $176K |
| ATP14 | <1% | 21,088 | $172K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14,461 | $171K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 577 | $171K |
| 80053 | Comprehensive metabolic panel | <1% | 60,308 | $166K |
| 70496 | <1% | 1,177 | $160K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,008 | $159K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,462 | $156K |
| 71250 | <1% | 2,919 | $152K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,020 | $134K |
| 81025 | <1% | 22,476 | $127K | |
| ATP08 | <1% | 18,390 | $125K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,446 | $125K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 53,263 | $117K |
| 87088 | <1% | 20,058 | $106K | |
| 73630 | <1% | 5,728 | $100K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,778 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 42,007 | $94K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 814 | $94K |
| 73564 | <1% | 3,620 | $90K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 280 | $89K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,375 | $88K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,213 | $88K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 606 | $86K |
| 83690 | <1% | 19,133 | $84K | |
| 76536 | <1% | 1,027 | $83K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 138 | $82K |
| 84702 | <1% | 6,402 | $81K | |
| 73030 | <1% | 4,130 | $77K | |
| 96367 | <1% | 509 | $75K | |
| 85027 | <1% | 18,884 | $72K | |
| 72100 | <1% | 2,791 | $72K | |
| 83735 | <1% | 22,530 | $72K | |
| 87480 | <1% | 4,548 | $72K | |
| 83655 | <1% | 6,288 | $72K | |
| 87510 | <1% | 4,548 | $71K | |
| 87660 | <1% | 4,547 | $71K | |
| 73610 | <1% | 4,892 | $71K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,321 | $66K |
| 80050 | General health panel | <1% | 4,339 | $65K |
| 83880 | <1% | 4,702 | $65K | |
| 73130 | <1% | 4,547 | $64K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,538 | $63K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 452 | $62K |
| 83605 | <1% | 10,653 | $61K | |
| 86803 | <1% | 5,956 | $61K | |
| 77080 | <1% | 1,573 | $61K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,497 | $60K |
| 80305 | <1% | 10,761 | $60K | |
| 87077 | <1% | 10,754 | $58K | |
| 87631 | <1% | 560 | $58K | |
| 94060 | <1% | 1,046 | $54K | |
| 87040 | <1% | 9,299 | $53K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 989 | $52K |
| 96415 | <1% | 244 | $52K | |
| 86780 | <1% | 4,501 | $51K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,930 | $50K |
| 77065 | Tomosynthesis, mammo | <1% | 1,243 | $49K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,200 | $49K |
| 81001 | <1% | 23,389 | $48K | |
| 86850 | <1% | 6,145 | $48K | |
| 87070 | <1% | 7,305 | $48K | |
| 87186 | <1% | 8,208 | $47K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 577 | $47K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,037 | $45K |
| 10060 | <1% | 286 | $45K | |
| 70486 | <1% | 565 | $44K | |
| 97162 | <1% | 740 | $43K | |
| 82728 | <1% | 5,172 | $42K | |
| 97165 | <1% | 523 | $41K | |
| 93017 | <1% | 605 | $40K | |
| 73110 | <1% | 2,971 | $40K | |
| 87081 | <1% | 7,177 | $40K | |
| ATP15 | <1% | 6,441 | $40K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,195 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,111 | $38K |
| 81003 | <1% | 23,879 | $37K | |
| 94729 | <1% | 1,313 | $36K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,405 | $36K |
| 94726 | <1% | 1,191 | $35K | |
| 73502 | <1% | 2,007 | $35K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 232 | $35K |
| 20610 | <1% | 232 | $35K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 27 | $35K |
| 77062 | <1% | 465 | $34K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,187 | $33K |
| 71271 | <1% | 1,018 | $33K | |
| 87340 | <1% | 3,929 | $32K | |
| 84703 | <1% | 5,494 | $32K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,939 | $32K |
| 80061 | Lipid panel | <1% | 16,035 | $31K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 189 | $29K |
| 82607 | <1% | 3,621 | $27K | |
| 84439 | <1% | 4,944 | $27K | |
| 90686 | <1% | 1,861 | $26K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 74 | $25K |
| 92557 | <1% | 294 | $24K | |
| 92567 | <1% | 505 | $24K | |
| 85610 | <1% | 12,806 | $23K | |
| 90715 | <1% | 1,195 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,916 | $22K |
| 86762 | <1% | 1,747 | $22K | |
| 83550 | <1% | 4,507 | $22K | |
| 85379 | <1% | 3,377 | $22K | |
| 74018 | <1% | 433 | $21K | |
| 86787 | <1% | 1,835 | $21K | |
| 73562 | <1% | 1,999 | $21K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 346 | $20K |
| 86618 | <1% | 1,674 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,332 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,555 | $19K |
| 86480 | <1% | 425 | $19K | |
| ATP17 | <1% | 3,971 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 128,642 | $18K |
| 83540 | <1% | 5,025 | $18K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,630 | $18K |
| 86900 | <1% | 6,422 | $17K | |
| 29125 | <1% | 121 | $17K | |
| 95070 | <1% | 15 | $17K | |
| 12002 | <1% | 78 | $17K | |
| 82803 | <1% | 1,246 | $15K | |
| 82746 | <1% | 2,134 | $15K | |
| 82951 | <1% | 967 | $15K | |
| 86901 | <1% | 6,416 | $14K | |
| 12011 | <1% | 67 | $14K | |
| 90714 | <1% | 489 | $13K | |
| 0012A | <1% | 519 | $13K | |
| 77061 | <1% | 166 | $13K | |
| 73140 | <1% | 605 | $12K | |
| 86140 | <1% | 3,578 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,765 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,294 | $12K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 70 | $11K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 321 | $11K |
| 82570 | <1% | 4,960 | $11K | |
| 0011A | <1% | 532 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 823 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,601 | $10K |
| 70491 | <1% | 130 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,182 | $10K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 128 | $10K |
| 73080 | <1% | 850 | $10K | |
| 85651 | <1% | 4,096 | $10K | |
| 87205 | <1% | 3,396 | $9K | |
| 76882 | <1% | 162 | $9K | |
| 70498 | <1% | 1,084 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,932 | $9K |
| 84153 | <1% | 1,755 | $9K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,556 | $9K |
| 87522 | Neg quan hep c or qual rna | <1% | 372 | $9K |
| 83970 | <1% | 750 | $9K | |
| ATP03 | <1% | 3,275 | $9K | |
| 80076 | <1% | 10,227 | $8K | |
| 82962 | <1% | 28,478 | $8K | |
| 76870 | <1% | 112 | $8K | |
| 97014 | <1% | 22 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,068 | $7K |
| 86706 | <1% | 1,102 | $7K | |
| A9270 | Non-covered item or service | <1% | 8,111 | $7K |
| 97035 | <1% | 70 | $7K | |
| 82784 | <1% | 771 | $7K | |
| 43235 | <1% | 12 | $7K | |
| 72050 | <1% | 179 | $7K | |
| 82043 | <1% | 3,195 | $6K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 39 | $6K |
| 86141 | <1% | 603 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,237 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 154 | $6K |
| 80197 | <1% | 2,462 | $5K | |
| 0001A | <1% | 142 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,187 | $5K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 184 | $5K |
| 80164 | <1% | 919 | $5K | |
| 87807 | <1% | 414 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,239 | $5K |
| 85730 | <1% | 1,550 | $5K | |
| 82950 | <1% | 1,072 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 142 | $4K |
| J3490 | Unclassified drugs | <1% | 373 | $4K |
| 0002A | <1% | 112 | $4K | |
| 99152 | <1% | 1,319 | $4K | |
| 86038 | <1% | 571 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,318 | $4K |
| ATP11 | <1% | 780 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,182 | $4K |
| 97802 | <1% | 46 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,509 | $4K |
| 88341 | <1% | 134 | $4K | |
| 84403 | <1% | 207 | $4K | |
| ATP10 | <1% | 749 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,816 | $4K |
| ATP02 | <1% | 1,014 | $4K | |
| 11102 | <1% | 12 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,474 | $3K |
| 73590 | <1% | 441 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 859 | $3K |
| 96368 | <1% | 117 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 212 | $3K |
| 94070 | <1% | 15 | $3K | |
| 88304 | <1% | 795 | $3K | |
| 88342 | <1% | 562 | $3K | |
| ATP18 | <1% | 609 | $3K | |
| 86704 | <1% | 410 | $3K | |
| 98926 | <1% | 60 | $2K | |
| 17110 | <1% | 14 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,472 | $2K |
| 97803 | <1% | 31 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 88 | $2K |
| 90651 | <1% | 12 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,027 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 125 | $2K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 16 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 771 | $2K |
| 82550 | <1% | 2,699 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,327 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 574 | $2K |
| 84466 | <1% | 217 | $2K | |
| ATP09 | <1% | 290 | $2K | |
| 85652 | <1% | 912 | $2K | |
| 73090 | <1% | 219 | $1K | |
| 82105 | <1% | 123 | $1K | |
| 90656 | <1% | 68 | $1K | |
| 82077 | <1% | 1,764 | $1K | |
| 86003 | <1% | 14 | $1K | |
| 72110 | <1% | 28 | $1K | |
| 71101 | <1% | 111 | $1K | |
| ATP07 | <1% | 254 | $1K | |
| 96376 | <1% | 2,740 | $986.86 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 330 | $973.03 |
| 84100 | <1% | 5,562 | $972.99 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 853 | $952.09 |
| 77091 | <1% | 325 | $942.71 | |
| ATP16 | <1% | 210 | $937.34 | |
| 90732 | <1% | 71 | $898.87 | |
| 97116 | <1% | 142 | $853.46 | |
| 85018 | <1% | 887 | $748.66 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,011 | $744.98 |
| 74019 | <1% | 105 | $720.96 | |
| 80178 | <1% | 244 | $700.50 | |
| 74174 | <1% | 15 | $682.20 | |
| 86364 | <1% | 67 | $630.05 | |
| 94010 | <1% | 12 | $607.69 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,308 | $606.27 |
| 84450 | <1% | 581 | $595.23 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,229 | $590.45 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,999 | $579.77 |
| V5266 | Battery for use in hearing device | <1% | 16 | $572.16 |
| 82565 | <1% | 1,545 | $543.15 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,438 | $523.25 |
| 85014 | <1% | 639 | $519.95 | |
| 76801 | <1% | 24 | $493.35 | |
| 86592 | <1% | 169 | $485.63 | |
| 0003A | <1% | 16 | $458.70 | |
| 76376 | <1% | 1,009 | $419.80 | |
| 86665 | <1% | 26 | $416.00 | |
| 90746 | <1% | 17 | $390.55 | |
| 84156 | <1% | 214 | $389.55 | |
| 99218 | <1% | 26 | $374.19 | |
| 72072 | <1% | 14 | $367.75 | |
| 83001 | <1% | 27 | $366.18 | |
| 86431 | <1% | 95 | $352.38 | |
| 74022 | <1% | 31 | $341.56 | |
| 94664 | <1% | 279 | $340.11 | |
| 84460 | <1% | 737 | $324.03 | |
| 84165 | <1% | 67 | $307.60 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 234 | $300.86 |
| 86258 | <1% | 14 | $284.76 | |
| 86308 | <1% | 65 | $278.10 | |
| 83615 | <1% | 654 | $265.25 | |
| 83516 | <1% | 17 | $263.00 | |
| 87427 | <1% | 26 | $253.33 | |
| 86200 | <1% | 25 | $205.56 | |
| 84402 | <1% | 12 | $202.14 | |
| 82378 | <1% | 41 | $200.64 | |
| 87210 | <1% | 45 | $198.00 | |
| 84146 | <1% | 15 | $194.37 | |
| 87045 | <1% | 24 | $180.17 | |
| 87046 | <1% | 24 | $180.17 | |
| 86664 | <1% | 13 | $175.37 | |
| 83002 | <1% | 13 | $168.90 | |
| 84163 | <1% | 12 | $164.88 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 321 | $155.38 |
| 80051 | <1% | 12 | $139.07 | |
| G0008 | Administration of influenza virus vaccine | <1% | 493 | $126.17 |
| 82150 | <1% | 25 | $100.20 | |
| 84520 | <1% | 825 | $94.96 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 205 | $88.60 |
| 86800 | <1% | 14 | $84.18 | |
| 82140 | <1% | 13 | $79.74 | |
| 85045 | <1% | 48 | $73.92 | |
| 80069 | <1% | 327 | $62.44 | |
| 82947 | <1% | 130 | $52.65 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 643 | $52.01 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,100 | $51.70 |
| 82952 | <1% | 13 | $44.98 | |
| 84550 | <1% | 195 | $37.75 | |
| 73060 | <1% | 15 | $37.21 | |
| 82248 | <1% | 293 | $36.86 | |
| 82270 | <1% | 14 | $30.24 | |
| 80143 | <1% | 321 | $15.31 | |
| 80179 | <1% | 243 | $15.31 | |
| 84478 | <1% | 12 | $13.33 | |
| 84155 | <1% | 30 | $9.72 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 357 | $7.83 |
| 82247 | <1% | 20 | $4.43 | |
| 82040 | <1% | 17 | $4.37 | |
| 99406 | <1% | 72 | $3.49 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 379 | $0.13 |
| 76942 | 0% | 14 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 501 | $0.00 |
| 94150 | 0% | 47 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 488 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 14 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 168 | $0.00 |
| 91300 | 0% | 168 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 48 | $0.00 |
| 87469 | 0% | 14 | $0.00 | |
| 90670 | 0% | 32 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 53 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 49 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 66 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| 77002 | 0% | 15 | $0.00 | |
| J2359 | Injection, olanzapine, 0.5 mg | 0% | 20 | $0.00 |
| 91312 | 0% | 12 | $0.00 | |
| 94760 | 0% | 578 | $0.00 | |
| 88738 | 0% | 546 | $0.00 | |
| 94761 | 0% | 568 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 629 | $0.00 |
| 36416 | 0% | 114 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 175 | $0.00 |
| 88311 | 0% | 15 | $0.00 | |
| 95012 | 0% | 71 | $0.00 | |
| 99292 | 0% | 13 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 327 | $0.00 |
| 36591 | 0% | 548 | $0.00 | |
| 87484 | 0% | 15 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 442 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 97 | $0.00 |
| 83521 | 0% | 13 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 20 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 123 | $0.00 |
| 91301 | 0% | 530 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 48 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 27 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 70 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| 87478 | 0% | 14 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| 87468 | 0% | 15 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRONHARD, JOHN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Umass Memorial Health-Harrington Hospital INC | Southbridge, MA | $71.31M |
| Umass Memorial Healthalliance Clinton Hospital INC | Clinton, MA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.